ADARx Pharmaceuticals has filed for an initial public offering with three drugs in the clinic, seeking to capitalize on renewed IPO momentum in biotech. The RNA interference company positions its pipeline as an emerging platform story as it transitions from private development into public capital markets. The filing underscores how investors are still underwriting modality-specific risk when clinical programs are advancing. It also raises attention on de-risking milestones for RNA-based therapies, including dosing, target engagement, and safety as programs move through later stages. For biotech professionals, the move is a signal to watch for upcoming terms, offer size, and the cadence of follow-on funding once public trading begins.